Lilly to participate in J.P. Morgan Healthcare Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Leerink on Eli Lilly (LLY): 'Orforglipron Delivers Weight Maintenance Following Injectables'
December 18, 2025 11:10 AM ESTLeerink Partners analyst David Risinger reiterated an Outperform rating and $1,104.00 price target on Eli Lilly (NYSE: LLY).
The analyst comments "We believe new maintenance data for LLYs oral once-daily GLP-1 candidate orforglipron will help drive commercial success and upside to consensus expectations. Our published orforglipron sales estimates vs. consensus are as follows: 2026E $2.0B vs. $1.4B, 2027E $9.0B vs. $3.3B, and 2028E $16.0B vs. $5.3B... More
